The Numbers From the Phase 2 Trial

The most robust data source on retatrutide and weight loss to date is the randomized, placebo-controlled Phase 2 trial by Jastreboff et al., published in the New England Journal of Medicine (2023). 338 adults with obesity (without type 2 diabetes) received weekly doses of 1, 4, 8, or 12 mg of retatrutide, or placebo, over 48 weeks.

After 48 weeks, mean weight reduction was 22.8% (8 mg) and 24.2% (12 mg), unadjusted for placebo. Placebo-adjusted, the 12 mg dose showed an effect of roughly 16% at 24 weeks and roughly 22% at 48 weeks. Nearly all participants in the 8 mg and 12 mg groups achieved at least 5% weight loss.

How the Dose Was Escalated in the Trial

Participants did not start directly at the target dose. As with other GLP-1-based compounds, the dose was increased gradually over several weeks to limit gastrointestinal side effects (mainly nausea). This titration logic is why single-dose figures without their time context are of limited value.

The most commonly reported side effects were gastrointestinal (nausea, diarrhea, constipation), mostly during the dose-escalation phase. An occasional moderate increase in heart rate was observed.

Why Community Reports Aren't Directly Comparable

Forums and subreddits around research peptides circulate anecdotal reports of 1–3 lbs of weight loss per week at maintenance dose. Such reports are uncontrolled, unblinded, and typically involve not pharmaceutical-grade material but research-grade product of unknown purity – a direct comparison with the controlled NEJM trial data is therefore not valid.

For an accessible walkthrough of the dose-escalation logic behind the trial data, the video "Retatrutide Dosing Explained" by Dr. Alex Tatem offers an independent breakdown of the published numbers (external source, not a Peptura endorsement).

No Approval Status – Not a Usage Recommendation

Retatrutid-Produktseite." data-en="Retatrutide is not yet approved by the FDA or EMA; the Phase 3 TRIUMPH program is still ongoing. The figures cited here come from controlled clinical trials and are not a dosing recommendation for personal use. More on the compound and available research dosage variants: Retatrutide product page.">Retatrutid ist bislang nicht von der FDA oder EMA zugelassen; das Phase-3-Programm TRIUMPH läuft noch. Die hier zitierten Zahlen stammen aus kontrollierten klinischen Studien und sind keine Dosierungsempfehlung für den Eigengebrauch. Mehr zum Wirkstoff und den verfügbaren Dosierungsvarianten für die Forschung: Retatrutid-Produktseite.

Sources

  • Jastreboff AM, et al. NEJM. 2023;389(6):514–526. PMID 37366315
  • Rosenstock J, et al. The Lancet. 2023;402(10401):529–544. PMID 37385280
  • Dr. Alex Tatem, "Retatrutide Dosing Explained (Doctor Breaks Down the Data)", YouTube (externe Quelle, unabhängige Einordnung).

References without a PMID can be located via the respective publisher.